GVAG
JAZZ icon

Great Valley Advisor Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Great Valley Advisor Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260K Buy
1,080
+14
+1% +$3.07K ﹤0.01% 892
2026
Q1 		$202K Buy
+1,066
New +$186K ﹤0.01% 953
2023
Q1 		– Sell
-11,783
Closed -$1.88M – 734
2022
Q4 		$1.88M Buy
+11,783
New +$1.73M 0.1% 223

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Great Valley Advisor Group's JAZZ Position: Q2 2026 in Review

Great Valley Advisor Group increased its Jazz Pharmaceuticals (JAZZ) stake by 1.3% in Q2 2026, buying an estimated $3.07K and bringing the position to 1,080 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #892.

Great Valley Advisor Group first reported a position in JAZZ in Q4 2022 and has held it in 3 quarters since. The position peaked at $1.88M in Q4 2022. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Great Valley Advisor Group held 1,080 shares of Jazz Pharmaceuticals worth $260K as of Q2 2026.
  • Great Valley Advisor Group bought 14 Jazz Pharmaceuticals shares in Q2 2026, an estimated $3.07K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Great Valley Advisor Group's portfolio in Q2 2026, its #892 holding.
  • Great Valley Advisor Group first reported a position in Jazz Pharmaceuticals in Q4 2022 and has held it in 3 quarters since.
  • Great Valley Advisor Group's Jazz Pharmaceuticals position peaked at $1.88M in Q4 2022.
  • 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Great Valley Advisor Group's 13F filing for Q2 2026, filed 10 Aug 2026.